PROSPECT II
A large multi-center prospective study was designed to assess the ability of intravascular imaging to identify non-obstructive coronary plaque that may cause future adverse events. After successfully treating all flow-limiting lesions in patients with recent myocardial infarction, investigators performed NIRS+IVUS intravascular imaging of all three coronary arteries. Patients were then followed for any adverse events that may have been caused by previously identified untreated non-culprit lesions.PROSPECT ABSORB
A sub-study embedded in the present study. Patients with angiographically, non-obstructive lesions with site-determined IVUS plaque burden were randomized to treatment with a bioresorbable scaffold versus medical therapy alone. These patients underwent repeat angiography and intravascular imaging at 25 months.
An important finding was that lesions responsible for most of the future cardiac events were caused by plaques not identified by angiography and pressure wires, the methods in widespread use today. Instead, lesions that were both lipid-rich and had high plaque burden as detected by NIRS+IVUS denoted those plaques that were at highest risk for future adverse outcomes,” said David Erlinge, MD, PhD, from Lund University, Sweden, and co-chairman of the study.
This study, the first randomized trial of interventional treatment of non-flow-limiting vulnerable plaques, suggests that prophylactic plaque passivation with a scaffold or stent can safely convert an angiographically mild high-risk plaque into a more stable lesion. As these lesions are not being treated today, a large-scale trial is warranted to determine whether PCI of vulnerable plaques can improve clinical outcomes in these high-risk patients,” said Gregg W. Stone, MD, of the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai Hospital in New York, and co-chairman of PROSPECT II and PROSPECT ABSORB.
The Makoto™ Intravascular Imaging System and its accompanying Dualpro™ IVUS + NIRS catheter, is an FDA-cleared imaging system indicated for the detection of plaque and patients at higher risk of MACE.
To request more information on how to obtain the Makoto™ system, or to see a demo, CLICK HERE
View the PROSPECT ABSORB Substudy highlights and presentation at TCT 2020
VIEW STUDY HIGHLIGHTS View TCT Presentation© 2024 Infraredx™, Inc. All Rights Reserved Powered by Bloom Creative